KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Higuchi Y, Yasunaga JI, Mitagami Y, Tsukamoto H, Nakashima K, Ohshima K, Matsuoka M. HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.

    Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13740-13749. doi: 10.1073/pnas.1922884117. Epub 2020 May 29. PMID: 32471947; PMCID: PMC7306771.

  2. Ghosh AK, Kovela S, Osswald HL, Amano M, Aoki M, Agniswamy J, Wang YF, Weber IT, Mitsuya H.
    Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    J Med Chem. 2020 May 14;63(9):4867-4879. doi: 10.1021/acs.jmedchem.0c00202. PMID: 32348139; PMCID: PMC7425579

  3. Nakamura T, Nakamura T, Amano M, Miyakawa T, Yamagata Y, Matsuoka M, Nakata H.
    A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor.
    J Virol. 2020 Sep 15;94(19):e00486-20. doi: 10.1128/JVI.00486-20. PMID: 32611758; PMCID: PMC7495394

  4. Onitsuka K, Tokuda R, Kuwata-Higashi N, Kumamoto H, Aoki M, Amano M, Kohgo S, Das D, Haraguchi K, Mitsuya H, Imoto S.

    Synthesis and evaluation of the anti-hepatitis B virus activity of 4′-Azido-thymidine analogs and 4′-Azido-2′-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

    Nucleosides Nucleotides Nucleic Acids. 2019 Sep 12;1-12. doi: 10.1080/15257770.2019.1664749. [Epub ahead of print]. PMID: 31514570.

  5. Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N, Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y.

    Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.

    Cancer Sci. 2019 Oct;110(10):3275-3287. doi: 10.1111/cas.14154. Epub 2019 Aug 14. PMID: 31368616; PMCID: PMC6778635.

  6. Takamatsu Y, Aoki M, Bulut H, Das D, Amano M, Sheri VR, Kovari LC, Hayashi H, Delino NS, Ghosh AK, Mitsuya H.

    Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

    Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00372-19. doi: 10.1128/AAC.00372-19. PMID: 31085520; PMCID: PMC6658756.

  7. Amano M, Salcedo-Gómez PM, Yedidi RS, Zhao R, Hayashi H, Hasegawa K, Nakamura T, Martyr CD, Ghosh AK, Mitsuya H.

    Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

    Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00466-19. doi: 10.1128/AAC.00466-19. PMID: 31061155; PMCID: PMC6591644.

  8. Nakata H, Maeda K, Das D, Chang SB, Matsuda K, Rao KV, Harada S, Yoshimura K, Ghosh AK, Mitsuya H.

    Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.

    Sci Rep. 2019 Mar 18;9(1):4828. doi: 10.1038/s41598-019-41080-w. PMID: 30886166; PMCID: PMC6423129.

  9. Amano M, Bulut H, Tamiya S, Nakamura T, Koh Y, Mitsuya H.

    Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition.

    Sci Rep. 2019 Jul 8;9(1):9806. doi: 10.1038/s41598-019-46082-2. PMID: 31285456; PMCID: PMC6614453.

  10. Maeda M, Muraki Y, Kosaka T, Yamada T, Aoki Y, Kaku M, Kawaguchi T, Seki M, Tanabe Y, Fujita N, Morita K, Yanagihara K, Yoshida K, Niki Y.

    The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy.

    J Infect Chemother. 2019 Feb;25(2):83-88. doi: 10.1016/j.jiac.2018.11.001. Epub 2018 Nov 22. PMID: 30473181.

  11. Iriyama N, Sugimoto KJ, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi T.

    Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.

    Med Oncol. 2018 Sep 7;35(11):142. doi: 10.1007/s12032-018-1203-7. PMID: 30194496.

  12. Hosokawa K, Sugimori C, Ishiyama K, Takamatsu H, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura JI, Kanakura Y, Nakao S.

    Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure.

    Ann Hematol. 2018 Dec;97(12):2289-2297. doi: 10.1007/s00277-018-3443-1. Epub 2018 Jul 24. PMID: 30039297.

  13. Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

    Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.

    Ann Hematol. 2018 Nov;97(11):2081-2088. doi: 10.1007/s00277-018-3412-8. Epub 2018 Jun 26. PMID: 29946911.

  14. Kawaguchi T.

    [Management of paroxysmal nocturnal hemoglobinuria: an update].

    Rinsho Ketsueki. 2018;59(6):703-710. Japanese. doi: 10.11406/rinketsu.59.703. PMID: 29973448.

  15. Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, Wada K, Matsuda T, Akiyama H, Ikezoe T, Chiba S, Kanda Y, Kawaguchi T, Shichishima T, Nakakuma H, Okamoto S, Nishimura JI, Kanakura Y, Ninomiya H.

    Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.

    Int J Hematol. 2018 Jun;107(6):656-665. doi: 10.1007/s12185-018-2409-3. Epub 2018 Jan 30. Erratum in: Int J Hematol. 2018 Aug;108(2):233-235. PMID: 29383624.

  16. Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y.

    Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

    Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23. PMID: 29362980.

  17. Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

    Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.

    Med Oncol. 2018 May 30;35(7):99. doi: 10.1007/s12032-018-1159-7. PMID: 29846829.

  18. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

    Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.

    Leuk Lymphoma. 2018 May;59(5):1105-1112. doi: 10.1080/10428194.2017.1365858. Epub 2017 Aug 25. PMID: 28838287.

  19. Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T.

    Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

    Med Oncol. 2018 Feb 13;35(3):38. doi: 10.1007/s12032-018-1093-8. PMID: 29442179.

  20. Tokunaga K, Yamamura A, Ueno S, Kikukawa Y, Yamaguchi S, Hidaka M, Matsuno N, Kawaguchi T, Matsuoka M, Okuno Y.

    Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement.

    Intern Med. 2018 Feb 15;57(4):563-568. doi: 10.2169/internalmedicine.8912-17. Epub 2017 Nov 20. PMID: 29151502; PMCID: PMC5849554.

  21. Saburi M, Ogata M, Itani K, Kohno K, Soga Y, Kondo Y, Kawano Y, Nakayama T.

    Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma.

    J Clin Exp Hematop. 2018 Dec 13;58(4):175-179. doi: 10.3960/jslrt.18019. Epub 2018 Oct 10. PMID: 30305474; PMCID: PMC6407474.

  22. Oda S, Kawano Y, Okuno Y, Utsunomiya D, Nakaura T, Tsujita K, Yamashita Y.

    Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis.

    Radiol Case Rep. 2018 Oct 18;14(1):72-74. doi: 10.1016/j.radcr.2018.09.025. PMID: 30364800; PMCID: PMC6198104.

  23. Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM.

    Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

    Leukemia. 2018 Aug;32(8):1739-1750. doi: 10.1038/s41375-018-0161-6. Epub 2018 Jun 20. PMID: 29925904.

  24. Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM.

    Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation.

    Clin Cancer Res. 2018 May 15;24(10):2430-2439. doi: 10.1158/1078-0432.CCR-17-2003. Epub 2018 Feb 9. PMID: 29440174.

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.